Clinical Trials Browser

Phase 1 × Triple Negative Breast Neoplasms × apatinib × Clear all

NCT03945604 2022-08-12

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC

Phase 1 Completed

Triple Negative Breast Neoplasms

NCT03075462 2022-07-01

A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients

Phase 1 Completed

BreastGynecologic

Ovarian Neoplasms, Triple Negative Breast Neoplasms